The primary drivers for the increase in SG&A expense for the three months ended March 31, 2023, as compared to the same period ended March 31, 2022, were an increase in professional fees and services related to marketing and pharmacovigilance, non-cash shared-based compensation expense, and travel and related costs.

May 4, 2023 / CEO / receipt, needs a key / Peter Greenleaf, CEO | earnings call 2023-05-04 | transcript c27479a7-b761-4eda-b2fe-e4f3e147f616 | chars 15641-15958 | segment 15